Pfizer (PFE) Competitors

Pfizer logo
$25.50 -0.15 (-0.57%)
Closing price 02/14/2025 03:59 PM Eastern
Extended Trading
$25.74 +0.25 (+0.98%)
As of 02/14/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PFE vs. JNJ, ABBV, MRK, BMY, ZTS, RPRX, JAZZ, CORT, PRGO, and SUPN

Should you be buying Pfizer stock or one of its competitors? The main competitors of Pfizer include Johnson & Johnson (JNJ), AbbVie (ABBV), Merck & Co., Inc. (MRK), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Jazz Pharmaceuticals (JAZZ), Corcept Therapeutics (CORT), Perrigo (PRGO), and Supernus Pharmaceuticals (SUPN). These companies are all part of the "pharmaceuticals" industry.

Pfizer vs.

Pfizer (NYSE:PFE) and Johnson & Johnson (NYSE:JNJ) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, dividends, institutional ownership, community ranking, media sentiment, valuation, profitability and analyst recommendations.

Pfizer received 387 more outperform votes than Johnson & Johnson when rated by MarketBeat users. Likewise, 68.98% of users gave Pfizer an outperform vote while only 64.99% of users gave Johnson & Johnson an outperform vote.

CompanyUnderperformOutperform
PfizerOutperform Votes
1508
68.98%
Underperform Votes
678
31.02%
Johnson & JohnsonOutperform Votes
1121
64.99%
Underperform Votes
604
35.01%

Pfizer pays an annual dividend of $1.72 per share and has a dividend yield of 6.7%. Johnson & Johnson pays an annual dividend of $4.96 per share and has a dividend yield of 3.2%. Pfizer pays out 122.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Johnson & Johnson pays out 74.6% of its earnings in the form of a dividend. Pfizer has increased its dividend for 16 consecutive years and Johnson & Johnson has increased its dividend for 63 consecutive years.

Johnson & Johnson has a net margin of 18.20% compared to Pfizer's net margin of 12.62%. Johnson & Johnson's return on equity of 34.35% beat Pfizer's return on equity.

Company Net Margins Return on Equity Return on Assets
Pfizer12.62% 19.47% 8.09%
Johnson & Johnson 18.20%34.35%13.69%

Pfizer currently has a consensus target price of $31.92, suggesting a potential upside of 25.21%. Johnson & Johnson has a consensus target price of $170.67, suggesting a potential upside of 9.26%. Given Pfizer's higher probable upside, equities research analysts plainly believe Pfizer is more favorable than Johnson & Johnson.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pfizer
1 Sell rating(s)
8 Hold rating(s)
5 Buy rating(s)
2 Strong Buy rating(s)
2.50
Johnson & Johnson
0 Sell rating(s)
9 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.56

68.4% of Pfizer shares are held by institutional investors. Comparatively, 69.6% of Johnson & Johnson shares are held by institutional investors. 0.1% of Pfizer shares are held by company insiders. Comparatively, 0.2% of Johnson & Johnson shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Johnson & Johnson had 29 more articles in the media than Pfizer. MarketBeat recorded 131 mentions for Johnson & Johnson and 102 mentions for Pfizer. Johnson & Johnson's average media sentiment score of 1.38 beat Pfizer's score of 1.08 indicating that Johnson & Johnson is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Pfizer
69 Very Positive mention(s)
12 Positive mention(s)
12 Neutral mention(s)
2 Negative mention(s)
1 Very Negative mention(s)
Positive
Johnson & Johnson
107 Very Positive mention(s)
10 Positive mention(s)
10 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive

Johnson & Johnson has higher revenue and earnings than Pfizer. Pfizer is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pfizer$63.63B2.27$2.12B$1.4118.08
Johnson & Johnson$88.82B4.23$14.07B$6.6523.49

Pfizer has a beta of 0.64, indicating that its stock price is 36% less volatile than the S&P 500. Comparatively, Johnson & Johnson has a beta of 0.52, indicating that its stock price is 48% less volatile than the S&P 500.

Summary

Johnson & Johnson beats Pfizer on 16 of the 22 factors compared between the two stocks.

Get Pfizer News Delivered to You Automatically

Sign up to receive the latest news and ratings for PFE and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PFE vs. The Competition

MetricPfizerPharmaceutical IndustryMedical SectorNYSE Exchange
Market Cap$144.48B$6.86B$5.77B$20.30B
Dividend Yield6.66%2.89%5.26%3.68%
P/E Ratio18.089.6426.1045.86
Price / Sales2.27320.64470.0215.25
Price / Cash6.3675.4646.0920.34
Price / Book1.615.537.275.73
Net Income$2.12B$123.50M$3.19B$1.00B
7 Day Performance-1.01%0.44%1.46%0.61%
1 Month Performance-3.46%3.24%5.67%3.42%
1 Year Performance-5.96%3.21%23.68%17.45%

Pfizer Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PFE
Pfizer
4.9986 of 5 stars
$25.50
-0.6%
$31.92
+25.2%
-6.0%$146.38B$63.63B18.0888,000Insider Trade
Short Interest ↓
Positive News
JNJ
Johnson & Johnson
4.6383 of 5 stars
$153.60
+0.3%
$170.67
+11.1%
+0.3%$369.64B$88.82B23.09131,900Short Interest ↑
Analyst Revision
Positive News
ABBV
AbbVie
4.5142 of 5 stars
$189.56
-0.5%
$208.35
+9.9%
+10.7%$334.87B$56.33B78.9650,000Dividend Announcement
Positive News
MRK
Merck & Co., Inc.
5 of 5 stars
$86.61
-0.8%
$119.06
+37.5%
-34.0%$219.08B$64.17B12.8772,000Analyst Forecast
Options Volume
BMY
Bristol-Myers Squibb
4.4517 of 5 stars
$55.43
-2.5%
$57.86
+4.4%
+10.2%$112.35B$48.30B-12.5334,100Positive News
ZTS
Zoetis
4.8707 of 5 stars
$172.20
+0.4%
$214.00
+24.3%
-14.4%$77.68B$8.54B32.3614,100Earnings Report
Dividend Announcement
Analyst Forecast
Short Interest ↑
Analyst Revision
News Coverage
RPRX
Royalty Pharma
4.7623 of 5 stars
$31.61
-0.4%
$41.67
+31.8%
+10.4%$18.62B$2.36B16.3880Earnings Report
JAZZ
Jazz Pharmaceuticals
4.9791 of 5 stars
$122.78
+2.1%
$177.00
+44.2%
+9.6%$7.42B$3.83B17.292,800Analyst Upgrade
CORT
Corcept Therapeutics
4.3998 of 5 stars
$68.12
+0.2%
$88.25
+29.6%
+200.5%$7.12B$628.56M53.95300Insider Trade
Analyst Revision
News Coverage
PRGO
Perrigo
4.954 of 5 stars
$24.45
-0.6%
$35.00
+43.1%
-22.4%$3.34B$4.66B-20.899,140
SUPN
Supernus Pharmaceuticals
2.9733 of 5 stars
$37.79
-1.6%
$46.50
+23.1%
+41.9%$2.09B$651.97M35.31580

Related Companies and Tools


This page (NYSE:PFE) was last updated on 2/15/2025 by MarketBeat.com Staff
From Our Partners